References
1. Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol . 2009;68(3):318-9.
2. Pittock SJ, Fujihara K, Palace J, Berthele A, Jin Kim H, Oreja-Guevara C et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler . 2021:13524585211038291.
3. Knoll BM, Letendre L, Steensma DP. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2008 Nov;83(11):881-3. doi: 10.1002/ajh.21265. PMID: 18756538.
4. Tempark T, John S, Rerknimitr P, Satapornpong, Sukasem C. Drug-induced severe cutaneous adverse reactions: Insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol 2022;13:1-21.
5. Hillmen P, Muus P, Szer J, Hill A, Hochsmann B, Kulasekararaj A et al. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2016;91(3):E16-7.
6. Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open . 2013;3(11):e003573.
7. Debureaux PE, Kulasekararaj AG, Cacace F, Silva BGP, Calado RT, Barone F et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.Bone Marrow Transplant . 2021;56(10):2600-2.
8. Howard JF, Jr., Karam C, Yountz M, O’Brien FL, Mozaffar T. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol . 2021;8(7):1398-407.
9. Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol . 2020;21(1):245.